For too long, there have been substantial gaps between knowledge on effective treatments for drug abuse generated by clinical researchers and drug abuse treatment as practiced in community substance. The creation of enduring partnerships between researchers and community providers as envisioned by NIDA in creating the Clinical Trials Network represents a promising opportunity to improve the quality of drug abuse treatment in the United States and to generate important new knowledge about effective treatments applicable to diverse groups of drug abusers. We propose to utilize the Network as a platform on which to conduct an innovative series of Stage III research projects.
The specific aims are: A. To develop an infrastructure for drug abuse treatment research through a partnership of the Yale Division of Substance Abuse and a network of community treatment programs (CTPs) in New England in order to (1) conduct clinical trials in a number of areas, including pharmacologic, behavioral, combined pharmacologic/behavioral practice, and technology transfer research and (2) work collaborative with other Nodes in the NIDA Clinical Trials Network. B. In collaboration with the Steering Committee of the Clinical Trials Network and NIDA, to develop and organizing framework for the Network, including policies on protocol development and review, publications and dissemination, quality control and data management, selection of assessment batteries and outcome measures, treatment development and therapist training, and clinical care.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA013038-04S2
Application #
6754090
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Tai, Betty
Project Start
1999-09-30
Project End
2004-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
4
Fiscal Year
2003
Total Cost
$400,000
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Crist, R C; Doyle, G A; Nelson, E C et al. (2018) A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. Pharmacogenomics J 18:173-179
Crist, Richard C; Li, James; Doyle, Glenn A et al. (2018) Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate. Am J Drug Alcohol Abuse 44:431-440
Zhu, Yuhui; Evans, Elizabeth A; Mooney, Larissa J et al. (2018) Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. J Neuroimmune Pharmacol 13:488-497
Decker, Suzanne E; Morie, Kristen P; Malin-Mayo, Bo et al. (2018) Positive and negative affect in cocaine use disorder treatment: Change across time and relevance to treatment outcome. Am J Addict :
Hser, Yih-Ing; Huang, David; Saxon, Andrew J et al. (2017) Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine?+?Naloxone and Methadone. J Addict Med 11:63-69
Pan, Yue; Liu, Hongmei; Metsch, Lisa R et al. (2017) Factors Associated with HIV Testing Among Participants from Substance Use Disorder Treatment Programs in the US: A Machine Learning Approach. AIDS Behav 21:534-546
Hser, Yih-Ing; Evans, Elizabeth; Huang, David et al. (2016) Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 111:695-705
Hernández, Diana; Feaster, Daniel J; Gooden, Lauren et al. (2016) Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav 20:204-14
Gooden, Lauren; Metsch, Lisa R; Pereyra, Margaret R et al. (2016) Examining the Efficacy of HIV Risk-Reduction Counseling on the Sexual Risk Behaviors of a National Sample of Drug Abuse Treatment Clients: Analysis of Subgroups. AIDS Behav 20:1893-906
Schackman, Bruce R; Leff, Jared A; Barter, Devra M et al. (2015) Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction 110:129-43

Showing the most recent 10 out of 92 publications